Introduction
Liver cancer means malignant (cancerous) growth in the liver. It may start in liver cells themselves—primary liver cancer, most often hepatocellular carcinoma (HCC)—or arrive as metastatic disease when cancer from another organ spreads to the liver.
A liver tumour is not automatically cancer: benign masses such as hemangiomas or focal nodular hyperplasia do not behave like malignancy. Imaging and, when needed, biopsy distinguish harmless lesions from cancer.
Primary liver cancer is frequently linked to chronic hepatitis B or C, cirrhosis, long-term alcohol harm, aflatoxin exposure, smoking, and metabolic disease. Early disease may be silent; later stages bring weight loss, right-upper abdominal pain, jaundice, ascites, and fatigue.
This page focuses on malignant liver disease—types, risks, symptoms, diagnosis, surgery and locoregional therapies, systemic options, prevention, and when to seek care. It is distinct from general “liver disease” overviews and from cirrhosis alone, though cirrhosis is a major risk setting for HCC. Plans belong with a hepatology–oncology team.
Overview
Primary liver cancer begins in the liver (HCC from hepatocytes; less often intrahepatic cholangiocarcinoma or childhood hepatoblastoma). Secondary liver cancer is metastasis from colon, breast, stomach, pancreas, lung, or other sites—the liver’s rich blood flow makes it a common landing site.
Many cases are found late, which complicates cure. Surveillance ultrasound in people with cirrhosis or chronic viral hepatitis can catch HCC earlier, when resection, ablation, or transplant may still be curative.
Treatment selection uses tumour burden, liver function (often Child–Pugh class), performance status, and staging systems such as BCLC. Goals range from cure to disease control and palliative comfort.
- Malignant growth: primary (starts in liver) or metastatic (spreads to liver)
- Most common primary type in adults: hepatocellular carcinoma (HCC)
- Not every liver mass is cancer—benign tumours also occur
- Major risks: chronic hepatitis B/C, cirrhosis, toxins, alcohol, smoking, metabolic disease
- Early cancer often asymptomatic; later signs include pain, jaundice, weight loss, ascites
- Therapy may include resection, transplant, ablation, TACE/TARE, targeted drugs, immunotherapy, or palliative care
What happens in the body
Chronic inflammation and scarring create a field of damaged hepatocytes that accumulate genetic changes, allowing clones of cancer cells to grow, invade vessels, and seed metastases. Viral hepatitis and alcohol-related injury are classic drivers of this pathway.
Metastatic deposits arrive via portal or systemic blood flow from a distant primary. Paraneoplastic syndromes—rare immune or hormone-mediated effects—can affect muscles, endocrine balance, blood counts, or other organs without direct tumour invasion of those sites.
- Chronic injury → dysplasia → invasive carcinoma in primary disease
- HCC arises from hepatocytes; cholangiocarcinoma from bile-duct lining
- Metastases reflect the liver’s role as a vascular filter
- Underlying cirrhosis often limits how much liver can be safely removed
Signs and symptoms
Early liver cancer may cause no symptoms. As disease progresses, common features include:
- Unexplained weight loss
- Loss of appetite or early fullness after small meals
- Fatigue and generalised weakness
- Upper abdominal pain or discomfort, sometimes a right-upper mass
- Abdominal swelling from ascites
- Yellowing of skin and eyes (jaundice)
- Nausea or vomiting
- Leg swelling (edema)
- Fever in some cases
- In cirrhosis: sudden worsening of liver function, confusion (encephalopathy), dark stools or vomiting blood
- In metastatic disease: similar liver symptoms plus signs from the original cancer site
Causes and risk factors
Direct biological drivers and major risk amplifiers for malignant liver disease include:
- Chronic hepatitis B or hepatitis C infection
- Cirrhosis from alcohol, viral hepatitis, or fatty liver disease
- Aflatoxin exposure from mould-contaminated grains or nuts
- Industrial or environmental toxins (for example arsenic, vinyl chloride)
- Long-term heavy alcohol use
- Tobacco smoking
- Metabolic/genetic liver disorders such as hemochromatosis or Wilson disease
- Diabetes, obesity, and NAFLD/NASH pathways
- Age roughly 40–60 in many series; higher rates in men
- Family history of liver cancer or chronic liver disease
- Prolonged anabolic steroid exposure in some contexts
- Spread of cancer from another organ (metastatic liver involvement)
Diagnosis and evaluation
Imaging characterises most suspected HCC; biopsy is reserved for unclear cases:
- Abdominal ultrasound—often the first clue, especially in surveillance programmes
- Contrast-enhanced multiphase CT or MRI (triphasic protocols) to characterise lesions
- Classic HCC imaging features may allow treatment planning without biopsy
- Liver biopsy when imaging is inconclusive or the mass looks atypical
- Blood tests of liver function and, when useful, tumour markers as adjuncts—not stand-alone proof
- Staging for lymph-node or distant spread and assessment of residual liver function
- Search for an extrahepatic primary when metastases are suspected
Treatment and management
Options depend on cancer type, stage, tumour number/size, liver reserve, and overall health:
- Surgical resection (hepatectomy) when disease is confined and remaining liver is adequate—up to roughly 70–75% can be removed in healthy livers; more remnant is needed in cirrhosis
- Liver transplant for selected HCC within size/number criteria when underlying liver disease precludes resection
- Thermal ablation (radiofrequency or microwave) for small tumours
- TACE (chemoembolisation) or TARE (radioembolisation) to treat tumours via the arterial supply
- Targeted oral agents (for example sorafenib, regorafenib, lenvatinib) in advanced disease
- Immunotherapy alone or combined with anti-angiogenic therapy in eligible patients
- Precision external radiation, including highly conformal techniques, for selected tumours
- Systemic therapy, ablation, or embolisation for some metastatic liver deposits when the primary is controlled
- Palliative care for pain, ascites, nausea, fatigue, and emotional support in advanced stages
- Clinical trials when standard options are limited
Prevention, self-care, and lifestyle
Not every condition is fully preventable, but the steps below may lower risk or recurrence:
- Hepatitis B vaccination for eligible infants, adults, and high-risk groups
- Prevent hepatitis C through safer sex, never sharing needles, and sterile tattoo/piercing equipment; treat chronic infection with antivirals
- Limit or stop alcohol to reduce cirrhosis risk
- Maintain healthy weight, exercise, and a balanced diet to lower NAFLD risk
- Quit smoking
- Control diabetes and metabolic syndrome
- Store food to limit aflatoxin; avoid known industrial hepatotoxins when possible
- Regular surveillance imaging if you have cirrhosis or other high-risk chronic liver disease
Possible complications
Delay, missed care, or unsafe self-medication can raise the chance of complications in some cases:
- Local invasion, vascular invasion, and distant metastasis
- Liver failure when tumour and underlying disease destroy reserve
- Variceal bleeding, ascites, and encephalopathy in cirrhotic patients
- Paraneoplastic syndromes affecting hormones, blood counts, or other systems
- Treatment-related risks: post-resection liver insufficiency, procedure complications, drug toxicity
- Reduced quality of life from pain, jaundice, and cachexia in late disease
When to see a doctor or seek emergency care
Seek prompt medical advice or emergency care if any of the following apply—it is safer not to wait and see:
- Unexplained weight loss, lasting right-upper abdominal pain, or a new abdominal mass
- Jaundice, dark urine, pale stools, or progressive abdominal swelling
- Vomiting blood, black stools, or sudden confusion in known liver disease—emergency care
- Known cirrhosis or chronic hepatitis—ask about cancer surveillance schedules
- New liver lesions reported on imaging done for another reason
Living with the condition
Living with liver cancer means pairing oncology decisions with protection of remaining liver function—nutrition, alcohol abstinence, medicine review, and infection prevention all matter.
Ask your team how stage, Child–Pugh class, and tumour biology shape choices among resection, transplant listing, locoregional therapy, and systemic drugs. Second opinions at centres with liver-cancer programmes are common and appropriate.
Palliative and supportive care can run alongside active treatment to control symptoms and support families—it is not only an “end-stage” service.
Frequently asked questions
Is a liver tumour the same as liver cancer?
No. Tumour means any mass. Benign tumours exist; cancer means malignant growth. Imaging and sometimes biopsy tell them apart.
What is the difference between primary and secondary liver cancer?
Primary cancer starts in the liver. Secondary (metastatic) cancer starts elsewhere and spreads to the liver.
Can part of the liver be removed for cancer?
Yes, when tumours are limited and enough healthy liver will remain. The liver can regenerate after resection if reserve is adequate.
Does cirrhosis always mean liver cancer?
No, but cirrhosis greatly raises HCC risk and is why surveillance is recommended in many patients.
How is advanced liver cancer managed?
When surgery is not possible, targeted therapy, immunotherapy, radiation for symptoms, clinical trials, and palliative care are the main approaches.
Can liver cancer be prevented?
Not every case, but hepatitis B vaccination, hepatitis C prevention/treatment, alcohol limits, weight control, and toxin avoidance meaningfully lower risk.
Important caution
This article is general education about malignant liver disease. It is not a staging report, treatment prescription, or transplant-eligibility decision.
Imaging results and therapy choices should be reviewed with specialists experienced in hepatobiliary cancer.
Seek urgent care for bleeding, severe confusion, or rapidly worsening jaundice or pain.